Search

Your search keyword '"Cogan, Jacob C"' showing total 18 results
Start Over Author "Cogan, Jacob C"
18 results on '"Cogan, Jacob C"'

2. Patients recently treated for B-lymphoid malignancies show increased risk of severe COVID-19: a CCC19 registry analysisImpact of B-cell malignancy therapy on COVID-19 outcomes

Author

Rubinstein, Samuel M, Bhutani, Divaya, Lynch, Ryan C, Hsu, Chih-Yuan, Shyr, Yu, Advani, Shailesh, Mesa, Ruben A, Mishra, Sanjay, Mundt, Daniel P, Shah, Dimpy P, Sica, R Alejandro, Stockerl-Goldstein, Keith E, Stratton, Catherine, Weiss, Matthias, Beeghly-Fadiel, Alicia, Accordino, Melissa, Assouline, Sarit E, Awosika, Joy, Bakouny, Ziad, Bashir, Babar, Berg, Stephanie, Bilen, Mehmet Asim, Castellano, Cecilia A, Cogan, Jacob C, Kc, Devendra, Friese, Christopher R, Gupta, Shilpa, Hausrath, Daniel, Hwang, Clara, Johnson, Nathalie A, Joshi, Monika, Kasi, Anup, Klein, Elizabeth J, Koshkin, Vadim S, Kuderer, Nicole M, Kwon, Daniel H, Labaki, Chris, Latif, Tahir, Lau, Eric, Li, Xuanyi, Lyman, Gary H, McKay, Rana R, Nagaraj, Gayathri, Nizam, Amanda, Nonato, Taylor K, Olszewski, Adam J, Polimera, Hyma V, Portuguese, Andrew J, Puc, Matthew M, Razavi, Pedram, Rosovski, Rachel, Schmidt, Andrew, Shah, Sumit A, Shastri, Aditi, Su, Christopher, Torka, Pallawi, Wise-Draper, Trisha M, Zubiri, Leyre, Warner, Jeremy L, and Thompson, Michael A

Subjects
Rare Diseases, Clinical Research, Prevention, Cancer, Aetiology, 2.1 Biological and endogenous factors, COVID-19, COVID-19 Testing, Humans, Lymphatic Diseases, Neoplasms, Risk Factors, SARS-CoV-2, COVID-19 and Cancer Consortium
Abstract

Patients with B-lymphoid malignancies have been consistently identified as a population at high risk of severe COVID-19. Whether this is exclusively due to cancer-related deficits in humoral and cellular immunity, or whether risk of severe COVID-19 is increased by anticancer therapy, is uncertain. Using data derived from the COVID-19 and Cancer Consortium (CCC19), we show that patients treated for B-lymphoid malignancies have an increased risk of severe COVID-19 compared with control populations of patients with non-B-lymphoid malignancies. Among patients with B-lymphoid malignancies, those who received anticancer therapy within 12 months of COVID-19 diagnosis experienced increased COVID-19 severity compared with patients with non-recently treated B-lymphoid malignancies, after adjustment for cancer status and several other prognostic factors. Our findings suggest that patients recently treated for a B-lymphoid malignancy are at uniquely high risk for severe COVID-19.SignificanceOur study suggests that recent therapy for a B-lymphoid malignancy is an independent risk factor for COVID-19 severity. These findings provide rationale to develop mitigation strategies targeted at the uniquely high-risk population of patients with recently treated B-lymphoid malignancies. This article is highlighted in the In This Issue feature, p. 171.

Published
2022

6. Supplementary Figure from Patients Recently Treated for B-lymphoid Malignancies Show Increased Risk of Severe COVID-19

Author

Rubinstein, Samuel M., primary, Bhutani, Divaya, primary, Lynch, Ryan C., primary, Hsu, Chih-Yuan, primary, Shyr, Yu, primary, Advani, Shailesh, primary, Mesa, Ruben A., primary, Mishra, Sanjay, primary, Mundt, Daniel P., primary, Shah, Dimpy P., primary, Sica, R. Alejandro, primary, Stockerl-Goldstein, Keith E., primary, Stratton, Catherine, primary, Weiss, Matthias, primary, Beeghly-Fadiel, Alicia, primary, Accordino, Melissa, primary, Assouline, Sarit E., primary, Awosika, Joy, primary, Bakouny, Ziad, primary, Bashir, Babar, primary, Berg, Stephanie, primary, Bilen, Mehmet Asim, primary, Castellano, Cecilia A., primary, Cogan, Jacob C., primary, KC, Devendra, primary, Friese, Christopher R., primary, Gupta, Shilpa, primary, Hausrath, Daniel, primary, Hwang, Clara, primary, Johnson, Nathalie A., primary, Joshi, Monika, primary, Kasi, Anup, primary, Klein, Elizabeth J., primary, Koshkin, Vadim S., primary, Kuderer, Nicole M., primary, Kwon, Daniel H., primary, Labaki, Chris, primary, Latif, Tahir, primary, Lau, Eric, primary, Li, Xuanyi, primary, Lyman, Gary H., primary, McKay, Rana R., primary, Nagaraj, Gayathri, primary, Nizam, Amanda, primary, Nonato, Taylor K., primary, Olszewski, Adam J., primary, Polimera, Hyma V., primary, Portuguese, Andrew J., primary, Puc, Matthew M., primary, Razavi, Pedram, primary, Rosovski, Rachel, primary, Schmidt, Andrew, primary, Shah, Sumit A., primary, Shastri, Aditi, primary, Su, Christopher, primary, Torka, Pallawi, primary, Wise-Draper, Trisha M., primary, Zubiri, Leyre, primary, Warner, Jeremy L., primary, and Thompson, Michael A., primary

Published
2023
Full Text
View/download PDF

7. Data from Patients Recently Treated for B-lymphoid Malignancies Show Increased Risk of Severe COVID-19

Author

Rubinstein, Samuel M., primary, Bhutani, Divaya, primary, Lynch, Ryan C., primary, Hsu, Chih-Yuan, primary, Shyr, Yu, primary, Advani, Shailesh, primary, Mesa, Ruben A., primary, Mishra, Sanjay, primary, Mundt, Daniel P., primary, Shah, Dimpy P., primary, Sica, R. Alejandro, primary, Stockerl-Goldstein, Keith E., primary, Stratton, Catherine, primary, Weiss, Matthias, primary, Beeghly-Fadiel, Alicia, primary, Accordino, Melissa, primary, Assouline, Sarit E., primary, Awosika, Joy, primary, Bakouny, Ziad, primary, Bashir, Babar, primary, Berg, Stephanie, primary, Bilen, Mehmet Asim, primary, Castellano, Cecilia A., primary, Cogan, Jacob C., primary, KC, Devendra, primary, Friese, Christopher R., primary, Gupta, Shilpa, primary, Hausrath, Daniel, primary, Hwang, Clara, primary, Johnson, Nathalie A., primary, Joshi, Monika, primary, Kasi, Anup, primary, Klein, Elizabeth J., primary, Koshkin, Vadim S., primary, Kuderer, Nicole M., primary, Kwon, Daniel H., primary, Labaki, Chris, primary, Latif, Tahir, primary, Lau, Eric, primary, Li, Xuanyi, primary, Lyman, Gary H., primary, McKay, Rana R., primary, Nagaraj, Gayathri, primary, Nizam, Amanda, primary, Nonato, Taylor K., primary, Olszewski, Adam J., primary, Polimera, Hyma V., primary, Portuguese, Andrew J., primary, Puc, Matthew M., primary, Razavi, Pedram, primary, Rosovski, Rachel, primary, Schmidt, Andrew, primary, Shah, Sumit A., primary, Shastri, Aditi, primary, Su, Christopher, primary, Torka, Pallawi, primary, Wise-Draper, Trisha M., primary, Zubiri, Leyre, primary, Warner, Jeremy L., primary, and Thompson, Michael A., primary

Published
2023
Full Text
View/download PDF

9. Patients Recently Treated for B-lymphoid Malignancies Show Increased Risk of Severe COVID-19

Author

Rubinstein, Samuel M, Bhutani, Divaya, Lynch, Ryan C, Hsu, Chih-Yuan, Shyr, Yu, Advani, Shailesh, Mesa, Ruben A, Mishra, Sanjay, Mundt, Daniel P, Shah, Dimpy P, Sica, R Alejandro, Stockerl-Goldstein, Keith E, Stratton, Catherine, Weiss, Matthias, Beeghly-Fadiel, Alicia, Accordino, Melissa, Assouline, Sarit E, Awosika, Joy, Bakouny, Ziad, Bashir, Babar, Berg, Stephanie, Bilen, Mehmet Asim, Castellano, Cecilia A, Cogan, Jacob C, Kc, Devendra, Friese, Christopher R, Gupta, Shilpa, Hausrath, Daniel, Hwang, Clara, Johnson, Nathalie A, Joshi, Monika, Kasi, Anup, Klein, Elizabeth J, Koshkin, Vadim S, Kuderer, Nicole M, Kwon, Daniel H, Labaki, Chris, Latif, Tahir, Lau, Eric, Li, Xuanyi, Lyman, Gary H, McKay, Rana R, Nagaraj, Gayathri, Nizam, Amanda, Nonato, Taylor K, Olszewski, Adam J, Polimera, Hyma V, Portuguese, Andrew J, Puc, Matthew M, Razavi, Pedram, Rosovski, Rachel, Schmidt, Andrew, Shah, Sumit A, Shastri, Aditi, Su, Christopher, Torka, Pallawi, Wise-Draper, Trisha M, Zubiri, Leyre, Warner, Jeremy L, Thompson, Michael A, and COVID-19 and Cancer Consortium

Subjects
SARS-CoV-2, Prevention, COVID-19, COVID-19 Testing, Rare Diseases, COVID-19 and Cancer Consortium, Risk Factors, Clinical Research, Neoplasms, Humans, 2.1 Biological and endogenous factors, Aetiology, Lymphatic Diseases, Cancer
Abstract

Patients with B-lymphoid malignancies have been consistently identified as a population at high risk of severe COVID-19. Whether this is exclusively due to cancer-related deficits in humoral and cellular immunity, or whether risk of severe COVID-19 is increased by anticancer therapy, is uncertain. Using data derived from the COVID-19 and Cancer Consortium (CCC19), we show that patients treated for B-lymphoid malignancies have an increased risk of severe COVID-19 compared with control populations of patients with non-B-lymphoid malignancies. Among patients with B-lymphoid malignancies, those who received anticancer therapy within 12 months of COVID-19 diagnosis experienced increased COVID-19 severity compared with patients with non-recently treated B-lymphoid malignancies, after adjustment for cancer status and several other prognostic factors. Our findings suggest that patients recently treated for a B-lymphoid malignancy are at uniquely high risk for severe COVID-19.SignificanceOur study suggests that recent therapy for a B-lymphoid malignancy is an independent risk factor for COVID-19 severity. These findings provide rationale to develop mitigation strategies targeted at the uniquely high-risk population of patients with recently treated B-lymphoid malignancies. This article is highlighted in the In This Issue feature, p. 171.

Published
2022

10. Efficacy of a password‐protected, pill‐dispensing device with mail return capacity to enhance disposal of unused opioids after cancer surgery

Author

Cogan, Jacob C., primary, Accordino, Melissa K., additional, Beauchemin, Melissa P., additional, Spivack, John H., additional, Ulene, Sophie R., additional, Elkin, Elena B., additional, Melamed, Alexander, additional, Taback, Bret, additional, Wright, Jason D., additional, and Hershman, Dawn L., additional

Published
2022
Full Text
View/download PDF

18. New and Persistent Sedative-Hypnotic Use After Adjuvant Chemotherapy for Breast Cancer.

Author

Cogan JC, Raghunathan RR, Beauchemin MP, Accordino MK, Huang Y, Elkin EB, Melamed A, Wright JD, and Hershman DL

Subjects
Humans, Aged, United States epidemiology, Female, Drug Prescriptions, Medicare, Hypnotics and Sedatives adverse effects, Benzodiazepines adverse effects, Chemotherapy, Adjuvant adverse effects, Breast Neoplasms drug therapy, Breast Neoplasms chemically induced
Abstract

Background: Sedative-hypnotic medications are used to treat chemotherapy-related nausea, anxiety, and insomnia. However, prolonged sedative-hypnotic use can lead to dependence, misuse, and increased health-care use. We aimed to estimate the rates at which patients who receive adjuvant chemotherapy for breast cancer become new persistent users of sedative-hypnotic medications, specifically benzodiazepines and nonbenzodiazepine sedative-hypnotics (Z-drugs)., Methods: Using the MarketScan health-care claims database, we identified sedative-hypnotic-naïve patients who received adjuvant chemotherapy for breast cancer. Patients who filled 1 and more prescriptions during chemotherapy and 2 and more prescriptions up to 1 year after chemotherapy were classified as new persistent users. Univariate and multivariable logistic regression analyses were used to estimate odds of new persistent use and associated characteristics., Results: We identified 22 039 benzodiazepine-naïve patients and 23 816 Z-drug-naïve patients who received adjuvant chemotherapy from 2008 to 2017. Among benzodiazepine-naïve patients, 6159 (27.9%) filled 1 and more benzodiazepine prescriptions during chemotherapy, and 963 of those (15.6%) went on to become new persistent users. Among Z-drug-naïve patients, 1769 (7.4%) filled 1 and more prescriptions during chemotherapy, and 483 (27.3%) became new persistent users. In both groups, shorter durations of chemotherapy and receipt of opioid prescriptions were associated with new persistent use. Medicaid insurance was associated with new persistent benzodiazepine use (odds ratio = 1.88, 95% confidence interval = 1.43 to 2.47) compared with commercial or Medicare insurance., Conclusions: Patients who receive sedative-hypnotic medications during adjuvant chemotherapy for breast cancer are at risk of becoming new persistent users of these medications after chemotherapy. Providers should ensure appropriate sedative-hypnotic use through tapering dosages and encouraging nonpharmacologic strategies when appropriate., (© The Author(s) 2022. Published by Oxford University Press. All rights reserved. For permissions, please email: journals.permissions@oup.com.)

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results